Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Research analysts at Oppenheimer Holdings dropped their FY2020 EPS estimates for Intercept Pharmaceuticals in a research note issued to investors on Monday. Oppenheimer Holdings analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of $3.99 per share for the year, down from their prior forecast of $4.02. Oppenheimer Holdings currently has a “Outperform” rating and a $200.00 price target on the stock. Oppenheimer Holdings also issued estimates for Intercept Pharmaceuticals’ FY2021 earnings at $8.83 EPS.
Several other equities analysts have also weighed in on the company. Laidlaw reissued a “hold” rating and issued a $119.00 target price (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday. BMO Capital Markets raised their price target on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wedbush reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research report on Monday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research report on Sunday. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Intercept Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $196.39.
TRADEMARK VIOLATION WARNING: “Research Analysts Offer Predictions for Intercept Pharmaceuticals, Inc.’s FY2020 Earnings (ICPT)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/03/research-analysts-offer-predictions-for-intercept-pharmaceuticals-inc-s-fy2020-earnings-icpt.html.
Intercept Pharmaceuticals (NASDAQ ICPT) traded up 4.42% during mid-day trading on Tuesday, reaching $109.64. The company’s stock had a trading volume of 1,310,046 shares. The company’s market cap is $2.74 billion. The stock’s 50 day moving average is $124.94 and its 200 day moving average is $118.29. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $177.93.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 119.17% and a negative net margin of 543.35%. The business’s revenue for the quarter was up 459.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.14) EPS.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 1,118 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $119.00, for a total value of $133,042.00. Following the completion of the transaction, the chief marketing officer now directly owns 45,680 shares in the company, valued at $5,435,920. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 254 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $117.52, for a total value of $29,850.08. Following the completion of the transaction, the insider now owns 23,246 shares of the company’s stock, valued at $2,731,869.92. The disclosure for this sale can be found here. In the last three months, insiders sold 47,575 shares of company stock worth $6,144,469. 9.20% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in Intercept Pharmaceuticals by 0.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado increased its position in Intercept Pharmaceuticals by 1.1% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 43 shares in the last quarter. Janney Montgomery Scott LLC increased its position in Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 62 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 178 shares in the last quarter. Hedge funds and other institutional investors own 84.27% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
